A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK.

ABSTRACT: The COVID-19 pandemic has created many challenges in the management of immune thrombocytopenic purpura (ITP). The recommendation for avoidance of steroids by WHO led to the off-licence use, supported by NHS England, of thrombopoietin mimetics (TPO-RA) for newly diagnosed or relapsed ITP. This is a real-world prospective study which investigated the treatment patterns and outcomes in this setting. Twenty-four hospitals across the UK submitted 343 cases. Corticosteroids remain the mainstay of ITP treatment, but TPO-RAs were more effective. Incidental COVID-19 infection was identified in a significant number of patients (9·5%), while 14 cases were thought to be secondary to COVID-19 vaccination.

SUBMITTER: Rampotas A 

PROVIDER: S-EPMC8652653 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature